Eloralintide (LY3841136) is an investigational once-weekly injection from Eli Lilly that activates amylin receptors, which signal fullness after meals. It was designed to favour the amylin receptor over the related calcitonin receptor. It is approved nowhere as of October 2, 2026.
In its 48-week phase 2 trial in adults without diabetes, weight fell by up to 20.1% on 9 mg against 0.4% on placebo, under the efficacy estimand. Nausea depended on how the dose was started, and fatigue was common at higher doses.
Lilly is testing it alone in five ENLIGHTEN phase 3 trials and with tirzepatide as EloraTZP, which cut weight by up to 23.3% in a phase 2b trial in type 2 diabetes. Every comparison with retatrutide so far is across trials and cannot rank the two.
On this page
- What is eloralintide?
- Is it approved? Status and timeline
- How it works
- Clinical evidence: every trial so far
- Weight-loss results at a glance
- Side effects and tolerability
- How it compares, and why most comparisons fail
- Access and legality
- Frequently asked questions
- Related on Grey Peptides
- Sources
What is eloralintide?
Eloralintide is an investigational drug being developed by Eli Lilly for weight management, given as one injection under the skin each week. It was known by its development code, LY3841136, before it received its name. It is a 37-position analogue of amylin, a hormone that the pancreas releases with insulin after meals and that helps end a meal by signalling fullness.
Amylin-based drugs are a growing class in obesity drug development, alongside the GLP-1-based drugs. Eloralintide's distinguishing design choice is selectivity: Lilly built it to favour amylin receptors over the closely related calcitonin receptor, which cagrilintide, the amylin analogue in Novo Nordisk's CagriSema, also activates. Lilly is developing it on its own and in combination with tirzepatide, a pairing it calls EloraTZP.
Is it approved? Status and timeline
No. As of October 2, 2026, eloralintide is approved nowhere and Lilly has announced no filing date. The record so far:
| Milestone | Status |
|---|---|
| First trials in people: single doses (NCT05295940) and 12 weeks of multiple doses | ✅ Completed by January 2024; published October 2025 and January 2026 |
| Phase 2 obesity trial, 48 weeks (NCT06230523) | ✅ Published in The Lancet, November 6, 2025; registry results June 24, 2026 |
| ENLIGHTEN phase 3, five trials | 🔄 Recruiting; first started December 15, 2025; primary completions January to June 2028 (registry) |
| EloraTZP phase 2b in type 2 diabetes (NCT06603571) | ✅ Results announced September 30, 2026 (EASD 2026); not yet published |
| EloraTZP single-injection phase 3 | ⏳ Lilly plans to start by the end of 2026 |
| Application to any regulator | ⏳ None announced as of October 2, 2026 |
How it works
Amylin receptors are the calcitonin receptor paired with one of three accessory proteins, RAMP1 to RAMP3, giving the AMY1, AMY2 and AMY3 receptors. In cell assays eloralintide activated the human AMY1 receptor 12 times more potently than the calcitonin receptor and 11 times more potently than AMY3. Lilly says its effect on weight is likely mediated by satiety, the feeling of fullness, which reduces how much people eat.
Whether selectivity matters in people is still open. The supporting evidence so far is from rats: eloralintide caused less conditioned taste avoidance than cagrilintide, and its weight loss in obese rats came mostly from fat. The once-weekly schedule comes from a fatty diacid attached to Lys26, the kind of lipidation that lets long-acting peptides bind reversibly to albumin and stay in the blood for days.
Clinical evidence: every trial so far
Three primary papers have been published, all funded by Eli Lilly. The first trial in people gave single doses from 0.04 to 12 mg to 48 healthy volunteers. A 12-week multiple-dose study, published separately, gave 100 people with obesity or overweight 12 weeks of weekly doses, started at the full dose, with mean weight loss of 2.6% to 11.3% across the dose groups. The phase 2 trial then tested six dosing regimens against placebo for 48 weeks in 263 adults without diabetes, at 46 US centres.
Lilly has since announced, but not published, a 48-week phase 2b trial of eloralintide with tirzepatide in 367 adults with type 2 diabetes. ClinicalTrials.gov lists 22 eloralintide studies in all, including five phase 3 trials:
| Trial | Registry | Population | Planned size |
|---|---|---|---|
| ENLIGHTEN-1 | NCT07321886 | Obesity or overweight without type 2 diabetes | 1,980 |
| ENLIGHTEN-2 | NCT07282600 | Obesity or overweight with type 2 diabetes | 1,035 |
| ENLIGHTEN-3 | NCT07369011 | Obstructive sleep apnoea (co-primary: apnoea-hypopnoea index) | 800 |
| ENLIGHTEN-4 | NCT07353931 | Knee osteoarthritis pain (co-primary: WOMAC) | 900 |
| ENLIGHTEN-6 | NCT07392190 | Persistent obesity on a weekly incretin, added on | 900 |
Every ENLIGHTEN trial is double-blind and placebo-controlled, with the change in body weight at 64 weeks as a primary outcome. Two more Lilly trials (NCT07215559 and NCT07589608) test eloralintide with macupatide (LY3532226), another Lilly drug.
Weight-loss results at a glance
Phase 2, adults with obesity or overweight and no diabetes, 48 weeks (least-squares means under the efficacy estimand, from the registry record; The Lancet paper reports the same figures rounded):
| Group | Weight change at week 48 |
|---|---|
| 1 mg | -9.4% |
| 3 mg | -12.4% |
| 6 mg | -17.6% |
| 9 mg | -20.1% |
| 6 mg, then 9 mg | -19.9% |
| 3 to 6 to 9 mg | -16.5% |
| Placebo | -0.4% |
EloraTZP phase 2b, adults with obesity or overweight and type 2 diabetes, 48 weeks (Lilly's figures under the efficacy estimand; baseline HbA1c 8.1%):
| Group | Weight change | HbA1c change (points) |
|---|---|---|
| Eloralintide 9 mg + tirzepatide 15 mg | -23.3% | -2.9 |
| Eloralintide 6 mg + tirzepatide 10 mg | -19.9% | -2.6 |
| Eloralintide 6 mg + tirzepatide 5 mg | -19.4% | -2.7 |
| Eloralintide 3 mg + tirzepatide 5 mg | -13.2% | -2.2 |
| Tirzepatide 15 mg | -14.8% | -2.4 |
| Eloralintide 6 mg | -12.3% | -1.4 |
| Eloralintide 9 mg | -11.1% | -1.3 |
| Eloralintide 3 mg | -8.2% | -1.1 |
| Placebo | -3.0% | -0.3 |
Two cautions apply to both tables. The efficacy estimand reports what would have happened had everyone stayed on treatment, so it runs higher than an estimand that counts people who stopped. And the two trials enrolled different people, and weight loss tends to be smaller in type 2 diabetes: eloralintide 6 mg gave 17.6% in the first table and 12.3% in the second, and because the trials differ in population and design, neither figure predicts the other.
Side effects and tolerability
In phase 2, nausea depended on how treatment started. It affected 64% of people who began on 6 mg and 54% of those who began on 6 mg before moving to 9 mg, but 25% of those who climbed from 3 mg to 9 mg over eight weeks, against 14% on placebo. Fatigue was the other common effect, reaching 43% on 9 mg and 46% on the 6 to 9 mg scheme, against 12% on placebo. There were no deaths, and serious adverse events occurred in one to three people per group, including the placebo group.
In the 12-week phase 1 study, without escalation, the most common effects were decreased appetite (19%), headache (12%) and fatigue (11%), while diarrhoea, nausea and vomiting were infrequent. In the EloraTZP trial, between 10.8% and 27.0% of people on the combinations stopped because of adverse events, against 2.9% on tirzepatide alone and up to 10.8% on eloralintide alone; Lilly reported 16.7% on placebo without explaining it.
How it compares, and why most comparisons fail
No trial has compared eloralintide with retatrutide or cagrilintide (the EloraTZP trial did include a tirzepatide-alone group). The figures circulating side by side come from different trials, and they differ in who took part, how long the trial ran and which estimand was reported. The clearest case is the comparison with retatrutide, Lilly's triple agonist: its phase 3 trial in type 2 diabetes, TRIUMPH-2, reported 18.8% weight loss on 12 mg at 80 weeks counting everyone randomised, while EloraTZP's 23.3% is a 48-week figure that assumes nobody stopped. Our EloraTZP post sets out the differences in full.
Against cagrilintide the difference that can be stated is pharmacological, not clinical: cagrilintide also activates the calcitonin receptor, and eloralintide was designed not to. Whether that changes tolerability in people is what the trials will show.
Access and legality
Eloralintide is available only inside Eli Lilly's clinical trials. No regulator has approved it, so there is no prescription route and no approved product. Anything sold online as eloralintide is not a regulated medicine and its contents are unverified. The encyclopedia entry carries its status in sport and its structure.
Frequently asked questions
Is eloralintide FDA approved?
No. As of October 2, 2026 it is in phase 3 trials and approved by no regulator anywhere, and Lilly has announced no filing date. It is available only inside Lilly's clinical trials.
When could eloralintide be approved?
There is no date. The five ENLIGHTEN phase 3 trials list primary completion dates from January to June 2028 on ClinicalTrials.gov, and an application would normally follow their results.
How much weight did people lose on eloralintide?
In the 48-week phase 2 trial in adults without diabetes, weight fell 9.4% on 1 mg and up to 20.1% on 9 mg, against 0.4% on placebo, under the efficacy estimand, which assumes everyone stayed on treatment.
What is EloraTZP?
EloraTZP is Lilly's name for eloralintide combined with tirzepatide. In a 48-week phase 2b trial in adults with type 2 diabetes the top combination cut weight 23.3%, against 14.8% on tirzepatide 15 mg, under the efficacy estimand; between 10.8% and 27.0% of people on the combinations stopped because of side effects.
What are the side effects of eloralintide?
Nausea and fatigue were the most common in phase 2. Nausea reached 64% when treatment started at 6 mg and 25% when the dose climbed from 3 mg, against 14% on placebo; fatigue reached 43% on 9 mg, against 12%.
Is eloralintide better than retatrutide?
Nobody knows yet. No trial has compared them, and the published figures differ in population, length and estimand, so setting one number beside the other does not rank them.
Can I buy eloralintide?
Not legitimately. It is available only in Eli Lilly's clinical trials, and anything sold online as eloralintide is not a regulated medicine.
Related on Grey Peptides
Sources
Peer-reviewed papers read at their abstracts on PubMed, registry records read on ClinicalTrials.gov, and Lilly's announcement for results not yet published. All read October 2, 2026.
- Billings LK, et al. "Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial." Lancet. 2025;406(10520):2631-2643.
- Bhattachar S, et al. "Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept." Diabetes Obes Metab. 2026;28(4):2651-2660.
- Briere DA, et al. "Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept." Mol Metab. 2025;102:102271.
- Bellido V, et al. "Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial." Lancet. 2026.
- ClinicalTrials.gov: NCT06230523 (phase 2, results posted June 24, 2026), NCT06603571 (EloraTZP phase 2b), and the ENLIGHTEN records NCT07321886, NCT07282600, NCT07369011, NCT07353931 and NCT07392190. Read October 2, 2026.
- Eli Lilly and Company. EloraTZP (combination of eloralintide and tirzepatide) phase 2b results. News release, September 30, 2026. Read October 2, 2026.
- FDA Global Substance Registration System, UNII 73G3354J8W (eloralintide), and KEGG DRUG D12886. Read October 2, 2026.
Medical disclaimer: This page is for education only and is not medical advice. Eloralintide is investigational and not approved for use. Do not start, stop, or self-administer any drug based on this page; consult a licensed clinician.